rttnews.com
FDA Accepts Takeda's SBLA For ENTYVIO IV In Pediatric UC And Crohn's Disease
The FDA’s acceptance of Takeda’s sBLA is a regulatory step toward possibly approving IV vedolizumab for children with moderate‑to‑severe UC or Crohn’s. If approved, this would expand an existing adult IBD treatment to younger patients.
This news is an update on the review timeline rather than a change in available treatments today.
Pediatric patients and families with moderate‑to‑severe UC or Crohn’s, clinicians who treat pediatric IBD, researchers following pediatric biologic trials, and patients on biologic therapies.
What To Know
FDA has accepted Takeda’s supplemental Biologics License Application (sBLA) seeking approval of IV ENTYVIO (vedolizumab) for pediatric patients (ages 2+) with moderately to severely active ulcerative colitis and Crohn’s disease; a PDUFA date is set for Q1 2027.
Takeda also filed an MAA with the EMA and cites two Phase 3 pediatric trials (KEPLER for UC and WEBB for Crohn’s). This is a regulatory milestone that could expand an already approved adult biologic (vedolizumab/ENTYVIO) to children, pending FDA review.
The acceptance means the FDA will review the application and has set a target decision date, but it is not an approval and does not change treatment options yet.
If approved, IV vedolizumab would become an FDA‑approved treatment option for pediatric UC and Crohn’s, based on randomized Phase 3 studies; until the FDA decision and potential label changes, clinical practice and prescribing remain guided by current approvals and pediatric practice standards.
Why this article matters: Families and clinicians caring for children with moderate‑to‑severe IBD may see a new approved biologic option if the review leads to approval. The report is primarily a regulatory/industry update rather than new clinical data reporting.
The article reports regulatory filings supported by Phase 3 pediatric trials (KEPLER and WEBB) but does not present new trial results or safety data. Acceptance for review and a PDUFA date do not guarantee approval. Clinical practice should not change until formal regulatory approval and updated labeling occur.
The source is a business/finance news outlet reporting Takeda’s announcement rather than a primary clinical publication.
